Registered entities
REGENXBIO INC
Reg. No. 471851754United States
Regenxbio Inc.
Reg. No. 1590877United States
Innovation
114 patent families (15 granted) — focus: Human necessities, Chemistry & metallurgy, Operations & transport; filing pace steady. Cited 12,873 times.
| Year | Filings |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 7 |
| 2019 | 16 |
| 2020 | 20 |
| 2021 | 31 |
| 2022 | 48 |
| 2023 | 64 |
| 2024 | 58 |
| 2025 | 51 |
| 2026 | 16 |
Social engagement
Social engagement: 50.5K social following, 10 posts in the last 12 months — around the industry typical range.
Investor mix
17 investors on record; lead investors include Brookside Capital, Venrock, Vivo Capital; 2 have since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 9 | 53% |
| Private equity | 3 | 18% |
| Bank & private debt | 1 | 6% |
| Other / undisclosed | 4 | 24% |
Hiring activity
Hires occasionally
2 roles tracked across 1 of the last 12 months
23 Nov 2025 · Director, Medical Science Liaisons (Neuromuscular/DMD) · Riverside
Based on job postings tracked across public sources.
Recent activity
30 Jun 2026
Event
Paternal Project Muscular Dystrophy (PPMD) Annual Conference
29 Jun 2026
Milestone
AbbVie
24 Jun 2026
Milestone
regulatory